Novel Biomarkers for Early Detection of Acute Kidney Injury and Prediction of Long-Term Kidney Function Decline after Partial Nephrectomy.
IGFBP7
NGAL
NephroCheck
TIMP-2
acute kidney injury
biomarkers
partial nephrectomy
renal cell carcinoma
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
28 Mar 2023
28 Mar 2023
Historique:
received:
25
02
2023
revised:
20
03
2023
accepted:
27
03
2023
medline:
16
5
2023
pubmed:
16
5
2023
entrez:
16
5
2023
Statut:
epublish
Résumé
Identifying acute kidney injury (AKI) within few hours of onset is certainly helpful. However, early prediction of a long-term eGFR decline may be an even more important goal. Our aim was to identify and compare serum [creatinine, kineticGFR, cystatin C, neutrophil gelatinase-associated lipocalin (NGAL)] and urinary (NephroCheck, NGAL, proteinuria, albuminuria, acantocytes at urinary sediment) predictors of AKI that might efficiently predict long-term GFR decline after robotic Nephron-Spearing Surgery (rNSS). Monocentric prospective observational study. Patients scheduled for rNSS for suspected localized Renal Cell Carcinoma from May 2017 to October 2017 were enrolled. Samples were collected preoperatively and postoperatively (timepoints: 4 h, 10 h, 24 h, 48 h), while kidney function was re-assessed up to 24 months. 38 patients were included; 16 (42%) developed clinical AKI. The eGFR decline at 24 months was more pronounced after postoperative AKI (-20.75 vs. -7.20, NephroCheck and kineticGFR have emerged as promising noninvasive, accurate, and early biomarkers of postoperative AKI and long-term GFR decline after rNSS. Combining NephroCheck and kineticGFR in clinical practice would allow to identify high risk of postoperative AKI and long-term GFR decline as early as 10 h after surgery.
Sections du résumé
BACKGROUND
BACKGROUND
Identifying acute kidney injury (AKI) within few hours of onset is certainly helpful. However, early prediction of a long-term eGFR decline may be an even more important goal. Our aim was to identify and compare serum [creatinine, kineticGFR, cystatin C, neutrophil gelatinase-associated lipocalin (NGAL)] and urinary (NephroCheck, NGAL, proteinuria, albuminuria, acantocytes at urinary sediment) predictors of AKI that might efficiently predict long-term GFR decline after robotic Nephron-Spearing Surgery (rNSS).
METHODS
METHODS
Monocentric prospective observational study. Patients scheduled for rNSS for suspected localized Renal Cell Carcinoma from May 2017 to October 2017 were enrolled. Samples were collected preoperatively and postoperatively (timepoints: 4 h, 10 h, 24 h, 48 h), while kidney function was re-assessed up to 24 months.
RESULTS
RESULTS
38 patients were included; 16 (42%) developed clinical AKI. The eGFR decline at 24 months was more pronounced after postoperative AKI (-20.75 vs. -7.20,
CONCLUSIONS
CONCLUSIONS
NephroCheck and kineticGFR have emerged as promising noninvasive, accurate, and early biomarkers of postoperative AKI and long-term GFR decline after rNSS. Combining NephroCheck and kineticGFR in clinical practice would allow to identify high risk of postoperative AKI and long-term GFR decline as early as 10 h after surgery.
Identifiants
pubmed: 37189664
pii: biomedicines11041046
doi: 10.3390/biomedicines11041046
pmc: PMC10135876
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Urol. 2016 Mar;195(3):588-93
pubmed: 26433140
J Am Soc Nephrol. 2017 Dec;28(12):3699-3707
pubmed: 28808078
Nephron. 2015;131(2):107-12
pubmed: 26332325
Kidney Int. 2010 Mar;77(6):536-42
pubmed: 20042998
Can Urol Assoc J. 2010 Oct;4(5):337-43
pubmed: 20944808
JAMA. 2012 May 9;307(18):1941-51
pubmed: 22570462
J Am Soc Nephrol. 2014 May;25(5):1063-71
pubmed: 24357673
Diabetes Metab Syndr Obes. 2014 Sep 18;7:421-35
pubmed: 25258547
Clin Chem Lab Med. 2011 Dec 21;50(9):1581-4
pubmed: 22962213
BJU Int. 2018 Jan;121(1):93-100
pubmed: 28834125
Crit Care. 2013 Feb 06;17(1):R25
pubmed: 23388612
J Intensive Care. 2014 Apr 03;2(1):26
pubmed: 25520838
Urol Oncol. 2016 Jul;34(7):293.e1-293.e10
pubmed: 27033047
J Am Soc Nephrol. 2018 Jan;29(1):207-216
pubmed: 29018140
Eur Urol. 2018 Nov;74(5):661-667
pubmed: 30104082
Medicine (Baltimore). 2019 Jun;98(26):e16232
pubmed: 31261582
Eur Urol Focus. 2020 Mar 15;6(2):344-353
pubmed: 30309817
Crit Care. 2012 Jun 21;16(3):313
pubmed: 22721504
Clin Kidney J. 2019 May 10;13(1):46-54
pubmed: 32082552
World J Urol. 2019 Oct;37(10):2217-2223
pubmed: 30661106
Urol Oncol. 2014 Nov;32(8):1259-66
pubmed: 25129142
Clin J Am Soc Nephrol. 2015 Nov 6;10(11):1900-10
pubmed: 26342047
J Urol. 2016 Oct;196(4):989-99
pubmed: 27157369
Eur Urol. 2019 May;75(5):799-810
pubmed: 30803729
Int J Cardiol. 2013 Jul 31;167(2):426-9
pubmed: 22305809
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Sci Transl Med. 2020 Mar 25;12(536):
pubmed: 32213630
Oncotarget. 2017 Jul 06;8(65):109762-109771
pubmed: 29312646
Anesth Analg. 2020 Dec;131(6):1679-1692
pubmed: 33186157
J Am Soc Nephrol. 2013 May;24(6):877-88
pubmed: 23704286
Circulation. 2010 May 18;121(19):2117-22
pubmed: 20439784
Clin J Am Soc Nephrol. 2017 Jul 7;12(7):1057-1069
pubmed: 28483780
Crit Care. 2004 Aug;8(4):R204-12
pubmed: 15312219
JAMA Netw Open. 2020 Oct 1;3(10):e2019209
pubmed: 33021646
Eur Urol Oncol. 2020 Apr;3(2):209-215
pubmed: 31411993